(2β,3α,5α)-3-hydroxy-2-methoxyandrostan-17-one | 1394127-25-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (2β,3α,5α)-3-hydroxy-2-methoxyandrostan-17-one
• 英文别名: (2S,3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-2-methoxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
• CAS: 1394127-25-3
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.472
• InChiKey: GGSJZFPTKDRBBN-JLGUAMPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  23.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  46.53
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (2β,3α,5α)-3-hydroxy-2-methoxyandrostan-17-one 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 15.0h， 生成 (2β,3α,5α)-2-methoxy-3-(methoxymethoxy)-17-methylene-androstane
  参考文献：
  名称：

  NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS

  摘要：

  本公开涉及神经活性的13,17-取代类固醇，以及其药用盐，例如作为麻醉剂使用，和/或用于治疗与GABA功能和活性相关的疾病。本公开还涉及包含这些化合物的药物组合物。

  公开号：

  US20140249120A1
• 作为产物：
  描述：

  (3β,5α)-3-[(methylsulfonyl)oxy]androstan-17-one 在 硫酸 、 lithium bromide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 (2β,3α,5α)-3-hydroxy-2-methoxyandrostan-17-one
  参考文献：
  名称：

  Neurosteroid Analogues. 18. Structure–Activity Studies of ent-Steroid Potentiators of γ-Aminobutyric Acid Type A Receptors and Comparison of Their Activities with Those of Alphaxalone and Allopregnanolone

  摘要：

  A model of the alignment of neurosteroids and ent-neurosteroids at the same binding site on gamma-aminobutyric acid type A (GABA(A)) receptors was evaluated for its ability to identify the structural features in ent-neurosteroids that enhance their activity as positive allosteric modulators of this receptor. Structural features that were identified included: (1) a ketone group at position C-16, (2) an axial 4 alpha-OMe group, and (3) a C-18 methyl group. Two ent-steroids were identified that were more potent than the anesthetic steroid alphaxalone in their threshold for and duration of loss of the righting reflex in mice. In tadpoles, loss of righting reflex for these two ent-steroids 0 occurs with EC50 values similar to those found for allopregnanolone. The results indicate that ent-steroids have considerable potential to be developed as anesthetic agents and as drugs to treat brain disorders that are ameliorated by positive allosteric modulators of GABA(A) receptor function.

  DOI：

  10.1021/jm401577c

文献信息

• [EN] C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE<br/>[FR] STÉROÏDES NEUROACTIFS SUBSTITUÉS EN C17, C20 ET C21 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2018013613A1

  公开（公告）日：2018-01-18

  Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.

  本文描述了神经活性类固醇或其药用可接受盐。在某些实施例中，这些化合物被设想为GABA调节剂。还提供了包括本文描述的化合物的药物组合物以及使用和治疗方法，例如用于诱导镇静和/或麻醉。
• NEUROACTIVE 17(20)-Z-VINYLCYANO-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
  申请人：Covey Douglas

  公开号：US20140309443A1

  公开（公告）日：2014-10-16

  The present disclosure is generally directed to neuroactive 17(20)-Z-vinylcyano-substituted compound of Formula (I) and (II), as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

  本公开涉及一般指向化合物的神经活性17(20)-Z-乙烯基氰基取代物，其化学式为(I)和(II)，并且其药学上可接受的盐，例如用作麻醉剂，和/或用于治疗与GABA功能和活性相关的疾病。本公开还涉及包含这种化合物的药物组合物。
• Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
  申请人：Washington University

  公开号：US10160783B2

  公开（公告）日：2018-12-25

  The present disclosure is generally directed to neuroactive 13, 17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

  本公开总体上涉及本文提及的神经活性 13、17-取代类固醇及其药学上可接受的盐类，可用作麻醉剂和/或治疗与 GABA 功能和活性有关的疾病。本公开进一步涉及包含此类化合物的药物组合物。
• Neuroactive steroids, compositions, and uses thereof
  申请人：Sage Therapeutics, Inc.

  公开号：US11046728B2

  公开（公告）日：2021-06-29

  Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

  本文描述的是式 (I) 的神经活性类固醇： 或其药学上可接受的盐；其中 R1a 和 R1b 如本文所定义。在某些实施方案中，此类化合物被设想为 GABA 调节剂。本发明还提供了包含本发明化合物的药物组合物以及使用和治疗方法，例如用于诱导镇静和/或麻醉的方法。
• C17, C20, and C21 substituted neuroactive steroids and their methods of use
  申请人：Sage Therapeutics, Inc.

  公开号：US11396525B2

  公开（公告）日：2022-07-26

  Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.

  本文描述的是神经活性类固醇或其药学上可接受的盐。在某些实施方案中，此类化合物被设想为 GABA 调节剂。还提供了包含本文所述化合物的药物组合物以及使用和治疗方法，例如用于诱导镇静和/或麻醉的方法。